Global Custom Market Research Reports Provider Company

phone

Gastric Ulcers - Pipeline Review, H2 2018

  • Published Date: 11 Sep 2018
  • Number of Pages: 44
  • Category: Pharmaceuticals
  • Country: Global
Gastric Ulcers - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H2 2018, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape.

Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Gastric Ulcers - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Gastric Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gastric Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Ulcers (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Gastric Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastric Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastric Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Ulcers (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastric Ulcers (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastric Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct
Introduction
Global Markets Direct Report Coverage
Gastric Ulcers - Overview
Gastric Ulcers - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gastric Ulcers - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastric Ulcers - Companies Involved in Therapeutics Development
Boryung Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Kukje Pharmaceutical Industry Co Ltd
RaQualia Pharma Inc
XuanZhu Pharma Co Ltd
Gastric Ulcers - Drug Profiles
(lafutidine + irsogladine maleate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-1386 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-14012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-3571 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KJ-14001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMKS-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9X0123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tegoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastric Ulcers - Dormant Projects
Gastric Ulcers - Discontinued Products
Gastric Ulcers - Product Development Milestones
Featured News & Press Releases
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
Jun 01, 2007: AstraZenecas Prilosec Patents Upheld By Court
Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals
Oct 23, 2001: Prilosec US litigation
May 02, 2001: AstraZeneca Receives Six Months Market Exclusivity for Prilosec
May 02, 2001: Court Denies Generics Application for Summary Judgement on Prilosec Patent
Apr 23, 2001: AstraZeneca Files Lawsuit against Apotex Corporation and Torpharm for Patent Infringement
Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada
Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Gastric Ulcers, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Gastric Ulcers - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2018
Gastric Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2018
Gastric Ulcers - Pipeline by RaQualia Pharma Inc, H2 2018
Gastric Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H2 2018
Gastric Ulcers - Dormant Projects, H2 2018
Gastric Ulcers - Discontinued Products, H2 2018

List Of Figures


Number of Products under Development for Gastric Ulcers, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018 T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T

View Report

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018 Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4

View Report

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2018 Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports